[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Biomet Profile (Biomaterials): Global Market Share Analysis by Region, SWOT, Product Pipeline & Financials

July 2012 | 92 pages | ID: BC38206A23FEN
iData Research Inc.

US$ 1,995.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Biomet is one of the five largest orthopedic implant manufacturers in the world, with distribution in the U.S., Europe, Asia and a number of emerging markets. Throughout its history, the company has also expanded into areas such as sports medicine and dental medical devices. As of 2011, Biomet distributed products in approximately 90 countries across the globe, earning revenues in the billions. This report is a comprehensive overview of Biomet's business activities with an in-depth analysis of the company's market share and presence in global orthopedic large joint reconstructive device markets.


The information covered includes:
  • An overview of the company history and current product divisions
  • A summary of corporate financial metrics
  • A review of recently approved products and the results of preliminary clinical trials
  • An in-depth review of the strengths, weaknesses opportunities and threats (SWOT) to the company's orthopedic biomaterials divisions
  • A detailed look at the market share and performance of each division in various countries across the U.S., Europe and Asia. Whenever possible, market share and division revenues are examined by individual country for each region of the globe.
The key product areas covered in this report include:
  • Hip Reconstruction
  • Knee Reconstruction
The countries covered in this report include:
  • U.S.
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Benelux
  • Scandinavia
  • Switzerland
  • Austria
  • Portugal
  • Japan
  • Australia
  • South Korea
EXECUTIVE SUMMARY

1.1 REPORT OVERVIEW
1.2 CORPORATE OVERVIEW
1.3 CORPORATE REVENUE GROWTH BY BUSINESS UNIT
1.4 GLOBAL REVENUE BY REGION
1.5 GLOBAL MARKET SHARE BY MARKET SIZE
1.6 MARKET SHARE: ORTHOPEDIC BIOMATERIALS

RESEARCH METHODOLOGY

2.1 IDATA’S 9-STEP METHODOLOGY
  2.1.1 Step 1: Project Initiation & Team Selection
  2.1.2 Step 2: Prepare Data Systems and Perform Secondary Research
  2.1.3 Step 3: Preparation for Interviews & Questionnaire Design
  2.1.4 Step 4: Performing Primary Research
  2.1.5 Step 5: Research Analysis: Establishing Baseline Estimates
  2.1.6 Step 6: Market Forecast and Analysis
  2.1.7 Step 7: Identify Strategic Opportunities
  2.1.8 Step 8: Final Review and Market Release
  2.1.9 Step 9: Customer Feedback and Market Monitoring

BIOMET COMPANY OVERVIEW

3.1 INTRODUCTION
3.2 COMPANY PROFILE
  3.2.1 Business Units
    3.2.1.1 Orthopedic Reconstruction
    3.2.1.2 Orthopedic Trauma, Spine and Biologics
    3.2.1.3 Sports Medicine
    3.2.1.4 Craniomaxillofacial
    3.2.1.5 Dental
3.3 GLOBAL REVENUES
  3.3.1 Global Revenues by Division
  3.3.2 Global Revenues by Geography
3.4 COMPANY HISTORY
3.5 COMPANY INFORMATION
  3.5.1 Size
  3.5.2 Office and Facility Locations

FINANCIAL METRICS

4.1 INCOME STATEMENT
4.2 BALANCE SHEET
  4.2.1 Balance Sheet
  4.2.2 Company Debt

PRODUCT PIPELINE

5.1 ORTHOPEDIC BIOMATERIALS
  5.1.1 U.S. FDA Investigational Device Exemption (IDE)
    5.1.1.1 Platelet Rich Plasmas for Tennis Elbow
  5.1.2 U.S. FDA Phase 1 Trials
    5.1.2.1 Bone Marrow Aspirate Concentration for Critical Limb Ischemia
  5.1.3 U.S. FDA 510(k) Submissions
    5.1.3.1 Bone Marrow Concentration System
  5.1.4 European CE Mark Trials
    5.1.4.1 ChonDux Trail Suspension
    5.1.4.2 Fat Concentration System

SWOT ANALYSIS

6.1 ORTHOPEDIC BIOMATERIALS SWOT ANALYSIS
  6.1.1 Strengths
    6.1.1.1 Joint Reconstruction
    6.1.1.2 History in Orthopedic Biologics
    6.1.1.3 Market Leader in Cell Concentration Systems
    6.1.1.4 Restructured Management
  6.1.2 Weaknesses
    6.1.2.1 Competition from Larger Competitors
    6.1.2.2 Lack of Advanced Bone Graft Substitute Product
    6.1.2.3 Partial Reliance on Distributors in the United States
    6.1.2.4 High Debt Levels
    6.1.2.5 Spine and Trauma Fixation Divisions
    6.1.2.6 Staff Restructuring
  6.1.3 Opportunities
    6.1.3.1 Undeveloped Asian and Emerging Markets Presence
    6.1.3.2 Underdeveloped Hyaluronic Acid Viscosupplementation Potential
    6.1.3.3 Migration to Chinese Manufacturing
  6.1.4 Threats
    6.1.4.1 Cost Control
    6.1.4.2 Medical Conservatism
    6.1.4.3 Department of Justice Sanction
    6.1.4.4 European Sovereign Debt Crisis of 2010 and Onward
    6.1.4.5 Potential for Acquisition

ORTHOPEDIC BIOMATERIALS MARKET SHARE

7.1 MARKET INTRODUCTION
  7.1.1 Bone Graft Substitutes
    7.1.1.1 Introduction
    7.1.1.2 Indications
    7.1.1.3 Materials
  7.1.2 Cell Concentration
    7.1.2.1 Introduction
    7.1.2.2 Platelet Rich Plasma
    7.1.2.3 Bone Marrow Aspirate
  7.1.3 Hyaluronic Acid Viscosupplementation
    7.1.3.1 Introduction
    7.1.3.2 Benefits of Viscosupplementation
    7.1.3.3 Synovial Fluid
    7.1.3.4 Three-Injection Cycle Products
    7.1.3.5 Five-Injection Cycle Products
    7.1.3.6 Single-Injection Cycle Products
7.2 KEY PRODUCTS
  7.2.1 Bone Graft Substitutes
    7.2.1.1 Allograft / DBM
    7.2.1.2 Synthetic Bone Void Fillers
  7.2.2 Hyaluronic Acid Viscosupplementation
  7.2.3 Cell Concentration
7.3 MARKET SHARE AND REVENUE ANALYSIS
  7.3.1 Bone Graft Substitutes
    7.3.1.1 Global Market Share
    7.3.1.2 United States Market Share
    7.3.1.3 European Market Share by Country
    7.3.1.4 International Market Share
  7.3.2 Cell Concentration (Platelet and Bone Marrow)
    7.3.2.1 Global
    7.3.2.2 U.S. Market Share
    7.3.2.3 European and International Market Share
  7.3.3 Hyaluronic Acid Viscosupplementation
    7.3.3.1 Global
    7.3.3.2 U.S. Market Share
    7.3.3.3 European Market Share
    7.3.3.4 International Market Share

ABBREVIATIONS


More Publications